Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245231 | 0.88 | HRH1 (0.57) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL245516 | 0.85 | HRH1 (0.55) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL246662 | 0.81 | HRH1 (0.76) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL246664 | 0.81 | HRH1 (0.76) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL246198 | 0.80 | ALDH1A1 (0.45) | ALDH1A1TSHRKMT2AKDM4E | |
| Doxepin SCHEMBL28075931 | 0.74 | HTR2B (0.95) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Cidoxepin SCHEMBL29493441 | 0.74 | HTR2B (1.00) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Cidoxepin SCHEMBL684837 | 0.74 | HTR2B (1.00) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Doxepin SCHEMBL28054 | 0.74 | HTR2B (1.00) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Doxepin SCHEMBL31349647 | 0.74 | HTR2B (1.00) | HRH1KCNH2HTR2BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | claimed |
| EP-2666770-A1 | Process for obtaining olopatadine and intermediates | Crystal Pharma S.A.U (ES) | 2013-11-27 | — | — | EP | claimed |
| EP-2145882-B1 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA SAU (ES) | 2013-08-21 | — | — | EP | claimed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | claimed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| EP-2666770-A1 | Process for obtaining olopatadine and intermediates | Crystal Pharma S.A.U (ES) | 2013-11-27 | — | — | EP | disclosed |
| EP-2145882-B1 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA SAU (ES) | 2013-08-21 | — | — | EP | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | OXER1, AOC3, OPRD1 | HRH1 28/4885KCNH2 2550/4885HTR2B 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.